Emcure Reports Strong Q1 FY27 Results; Announces Key Board and Leadership Changes

Emcure Reports Strong Q1 FY27 Results; Announces Key Board and Leadership Changes​

Emcure Pharmaceuticals Limited announced its consolidated financial results for the first quarter of fiscal year 2027 (Q1 FY27) on August 6, 2026. The company reported substantial growth across key metrics, with revenue growing by 22.8% year-on-year and Profit After Tax (PAT) increasing by 36.2%.

The results underscore the momentum of Emcure’s strategic focus, as detailed in the accompanying Limited Review Report by M/s B S R & Co. LLP.

Q1 FY27 Consolidated Financial Performance Highlights​

Emcure's consolidated revenue from operations stood at INR 25,804 million. The company achieved EBITDA of INR 5,080 million, reflecting a margin improvement to 19.7%, which is up approximately 50 basis points year-on-year. PAT reached INR 2,925 million, corresponding to a 36.2% increase in the quarter.

The company’s domestic business generated INR 10,953 million, reflecting a 10.2% growth. Meanwhile, international sales were strong at INR 14,851 million, up 34.2%, constituting 57.6% of total consolidated revenue from operations.

The performance across geographies showed encouraging growth:

• Rest of World (RoW) grew by 44.8% to INR 5,218 million.
• Europe achieved a 32.8% growth, reaching INR 5,367 million.
• Canada saw a 24.6% increase in sales, amounting to INR 4,266 million.

The consolidated P&L summary provides insight into the financial structure:

Standalone Results and Business Insights​

The unaudited standalone financial results for the quarter also showed robust performance for Emcure Pharmaceuticals Limited, with total income reaching INR 14,759.63 million. The company continues to invest heavily in future growth, allocating INR 904 million towards R&D.

Regarding operational developments, the company reported that it completed the acquisition of a 12.05% minority stake in Gennova Biopharmaceuticals Limited (a subsidiary) during July 2026, making Gennova a wholly owned subsidiary. Furthermore, Emcure signed a royalty-free licensing agreement with MSD to produce a generic version of its experimental once monthly oral HIV pill (alimatravir) for low and lower middle income countries in July 2026.

Board and Leadership Transitions​

The Board meeting conducted on August 6, 2026, addressed several key leadership changes:

• Director Retirement: Mr. Berjis Desai, Chairman and a Non-executive, Non-Independent Director who is liable to retire by rotation at the ensuing Annual General Meeting (AGM), has expressed his unwillingness to seek re appointment due to his role as a member of the National Commission for Minorities, New Delhi. Consequently, he will cease to hold office as Chairman and Director of the Company with effect from the conclusion of the AGM.
• New Appointments: The Board approved the appointment of Mr. Raghu Kumar (DIN: 01983106) as an Additional Director (Non-Executive and Independent), effective August 6, 2026. He was later appointed as an Independent Director for the first term of three years, subject to AGM approval on September 21, 2026.
• Chairman Appointment: In view of Mr. Desai's retirement, the Board approved the appointment of Mr. Satish Mehta (DIN: 00118691), Managing Director & CEO, as the Chairman of the Company with effect from the conclusion of the ensuing AGM.
• COO Appointment: Based on a recommendation, the Board approved the immediate appointment of Mr. Samit Mehta (DIN: 00332562), Whole-time Director, as the Chief Operating Officer (COO) of the Company.

Committee Reconstitution​

The Board approved the re constitution of the Audit Committee, the Nomination and Remuneration Committee, and the Stakeholders' Relationship Committee, effective from the conclusion of the ensuing Annual General Meeting. These committees now include various directors to ensure oversight and governance moving forward.